Morgan Stanley lowered the firm’s price target on enGene (ENGN) to $18 from $19 and keeps an Overweight rating on the shares after the company reported Q3 results and reiterated clinical development timelines for detalimogene. The firm adjusting its model based on Q3 actual results drives its price target change, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Buy Rating for enGene Holdings: Strategic Positioning and Competitive Edge in NMIBC Market
- enGene Holdings Reports Q3 2025 Results and Milestones
- enGene Holdings Achieves Key Milestone in LEGEND Trial and Secures RMAT Designation
- enGene reports Q3 EPS 57c vs. 32c last year
- Citizens JMP healthcare analysts hold an analyst/industry conference call